Research Article: Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study
Introduction:
Esophageal cancer (EC) is the predominant malignant tumor of the digestive system. According to the latest global cancer data, EC has the seventh-highest incidence and sixth-highest fatality rate. Surgery alone does not significantly benefit patients with locally advanced esophageal squamous cell cancer (ESCC), with a -year overall survival (OS) of %, and a combination of surgery combined with chemotherapy, immunotherapy, and radiotherapy is the mainstay of treatment. Neoadjuvant therapy combined with surgery has…
Read more